NVP-BAW2881 (BAW2881) is a potent and selective VEGFR (vascular endothelial growth factor receptor tyrosine kinase) inhibitor with efficacy in inhibiting chronic and acute skin inflammation.

c-ABL:99 nM, VEGFR2 (human):9 nM, VEGFR1:820 nM, Tie2:650 nM, B-Raf (V599E):76 nM, VEGFR3:420 nM, VEGF2 (mouse):165 nM, C-Raf1:24 nM

In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells.

In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells.

HUVECs or LECs (1.2×103) were seeded into fibronectin-coated 96-well plates. After 24 hours, the cells were transferred into LEC medium containing 2% fetal bovine serum and incubated for an additional 24 hours. Cells(eight wells/condition) were incubated with medium alone(control), 20 ng/ml VEGF-A, or a combination of 20 ng/ml VEGF-A and 1 nmol/L to 1 mol/L NVP-BAW2881. Proliferation was also assayed in LECs incubated with 500 ng/ml VEGF-C. The dimethyl sulfoxide concentration was adjusted to 0.1% in all wells. After 72 hours, cells were incubated with 5-methylumbelliferylheptanoate for subsequent fluorescent quantification of viable cells, using a SpectraMax Gemini electron microscope. (Only for Reference)

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 78 mg/mL (183.8 mM), Sonication is recommended.

Ethanol: 16 mg/mL (37.7 mM), Sonication is recommended.

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.71 mM), Sonication is recommended.